Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
McKesson
Harvard Business School
Dow
Baxter

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

EUCRISA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Eucrisa patents expire, and when can generic versions of Eucrisa launch?

Eucrisa is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and twenty-three patent family members in twenty-four countries.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the crisaborole profile page.

Summary for EUCRISA
Drug patent expirations by year for EUCRISA
Drug Prices for EUCRISA

See drug prices for EUCRISA

Generic Entry Opportunity Date for EUCRISA
Generic Entry Date for EUCRISA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
OINTMENT;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EUCRISA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ann & Robert H Lurie Children's Hospital of ChicagoPhase 4
Innovaderm Research Inc.Phase 4
Johns Hopkins UniversityPhase 4

See all EUCRISA clinical trials

Pharmacology for EUCRISA
Synonyms for EUCRISA
1073669-75-6
1187189-21-4
4-((1-HYDROXY-1,3-DIHYDROBENZO-[C][1,2]OXABOROL-5-YL)OXY)BENZONITRILE
4-((1-Hydroxy-1,3-dihydrobenzo(c)(1,2)oxaborol-6-yl)oxy)benzonitrile
4-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile
4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)benzonitrile
4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile
4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile
4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile
5-(4-cyanophenoxy)-1-hydroxy-2,1-benzoxaborole
5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole
5098AC
906673-24-3
ABP001114
AC-30331
AK102641
AKOS016005425
AN 2728
AN-2728
AN2728
ANW-65536
API0013781
AX8234180
BC245091
BCP08677
BDBM50277665
Benzonitrile, 4-((1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy)-
Benzonitrile, 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]-
C14H10BNO3
CHEBI:134677
CHEMBL484785
compound 5b [PMID: 19303290]
Crisaborole
Crisaborole (USAN/INN)
Crisaborole [USAN:INN]
Crisaborole topical ointment 2%
Crisaborole, >=98% (HPLC)
Crisaborole(AN-2728)
CS-1057
CTK8C0958
D10873
DB-078771
DB05219
DTXSID10238231
Eucrisa (TN)
EX-A1087
FT-0767999
GTPL9151
HY-10978
KB-40872
KS-0000063U
MolPort-023-332-548
NCGC00345792-01
NCGC00345792-02
Q2R47HGR7P
SB16802
SCHEMBL595261
ST24042710
TC-154281
UNII-Q2R47HGR7P
USZAGAREISWJDP-UHFFFAOYSA-N
W-5676
ZINC169748244

US Patents and Regulatory Information for EUCRISA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Medtronic
Boehringer Ingelheim
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.